363 related articles for article (PubMed ID: 11229405)
1. Protein design of an HIV-1 entry inhibitor.
Root MJ; Kay MS; Kim PS
Science; 2001 Feb; 291(5505):884-8. PubMed ID: 11229405
[TBL] [Abstract][Full Text] [Related]
2. Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity.
Louis JM; Bewley CA; Clore GM
J Biol Chem; 2001 Aug; 276(31):29485-9. PubMed ID: 11418583
[TBL] [Abstract][Full Text] [Related]
3. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.
Eckert DM; Kim PS
Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11187-92. PubMed ID: 11572974
[TBL] [Abstract][Full Text] [Related]
4. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements.
Ferrer M; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Wiley DC; Harrison SC
Nat Struct Biol; 1999 Oct; 6(10):953-60. PubMed ID: 10504731
[TBL] [Abstract][Full Text] [Related]
5. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation.
Kliger Y; Shai Y
J Mol Biol; 2000 Jan; 295(2):163-8. PubMed ID: 10623516
[TBL] [Abstract][Full Text] [Related]
7. Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides.
Shu W; Liu J; Ji H; Radigen L; Jiang S; Lu M
Biochemistry; 2000 Feb; 39(7):1634-42. PubMed ID: 10677212
[TBL] [Abstract][Full Text] [Related]
8. Interhelical interactions in the gp41 core: implications for activation of HIV-1 membrane fusion.
Wang S; York J; Shu W; Stoller MO; Nunberg JH; Lu M
Biochemistry; 2002 Jun; 41(23):7283-92. PubMed ID: 12044159
[TBL] [Abstract][Full Text] [Related]
9. A novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 Gp41 core structure.
Pang W; Wang RR; Gao YD; Yang LM; Sun Y; Huang JF; Tien P; Zheng YT
J Biomol Screen; 2011 Feb; 16(2):221-9. PubMed ID: 21297108
[TBL] [Abstract][Full Text] [Related]
10. The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20.
Trivedi VD; Cheng SF; Wu CW; Karthikeyan R; Chen CJ; Chang DK
Protein Eng; 2003 Apr; 16(4):311-7. PubMed ID: 12736375
[TBL] [Abstract][Full Text] [Related]
11. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
[TBL] [Abstract][Full Text] [Related]
12. Blocking HIV entry.
Buzko OV; Shokat KM
Nat Struct Biol; 1999 Oct; 6(10):906-8. PubMed ID: 10504719
[TBL] [Abstract][Full Text] [Related]
13. Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process.
Bär S; Alizon M
J Virol; 2004 Jan; 78(2):811-20. PubMed ID: 14694113
[TBL] [Abstract][Full Text] [Related]
14. C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread.
Medinas RJ; Lambert DM; Tompkins WA
J Virol; 2002 Sep; 76(18):9079-86. PubMed ID: 12186891
[TBL] [Abstract][Full Text] [Related]
15. HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides.
Liu S; Jing W; Cheung B; Lu H; Sun J; Yan X; Niu J; Farmar J; Wu S; Jiang S
J Biol Chem; 2007 Mar; 282(13):9612-9620. PubMed ID: 17276993
[TBL] [Abstract][Full Text] [Related]
16. Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1.
Jin BS; Ryu JR; Ahn K; Yu YG
AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1797-804. PubMed ID: 11118065
[TBL] [Abstract][Full Text] [Related]
17. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target.
Chan DC; Chutkowski CT; Kim PS
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15613-7. PubMed ID: 9861018
[TBL] [Abstract][Full Text] [Related]
18. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates.
Golding H; Zaitseva M; de Rosny E; King LR; Manischewitz J; Sidorov I; Gorny MK; Zolla-Pazner S; Dimitrov DS; Weiss CD
J Virol; 2002 Jul; 76(13):6780-90. PubMed ID: 12050391
[TBL] [Abstract][Full Text] [Related]
19. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.
Lawless MK; Barney S; Guthrie KI; Bucy TB; Petteway SR; Merutka G
Biochemistry; 1996 Oct; 35(42):13697-708. PubMed ID: 8885850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
